The FDA granted a new indication for ibrutinib (Imbruvica, Janssen Biotech-Pharmacyclics) to treat patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20–based therapy.
JANUARY 19, 2017
JANUARY 19, 2017
The FDA granted a new indication for ibrutinib (Imbruvica, Janssen Biotech-Pharmacyclics) to treat patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20–based therapy.